HAEMONETICS CORP Insider Trading for November 2017
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in HAEMONETICS CORP.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in HAEMONETICS CORP for November 2017.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Nov 17 2017 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Option Exercise | M | 34.41 | 1,678 | 57,732 | 0 | |
Nov 17 2017 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Option Exercise | M | 34.41 | 5,440 | 187,163 | 1,678 | |
Nov 17 2017 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Buy | M | 34.41 | 1,678 | 57,732 | 55,695 | 54 K to 55.7 K (+3.11 %) |
Nov 17 2017 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Sell | S | 56.80 | 300 | 17,040 | 54,017 | 54.3 K to 54 K (-0.55 %) |
Nov 17 2017 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Sell | S | 56.78 | 200 | 11,356 | 54,317 | 54.5 K to 54.3 K (-0.37 %) |
Nov 17 2017 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Sell | S | 56.77 | 300 | 17,031 | 54,517 | 54.8 K to 54.5 K (-0.55 %) |
Nov 17 2017 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Sell | S | 56.74 | 300 | 17,021 | 54,817 | 55.1 K to 54.8 K (-0.54 %) |
Nov 17 2017 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Sell | S | 56.73 | 400 | 22,692 | 55,117 | 55.5 K to 55.1 K (-0.72 %) |
Nov 17 2017 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Sell | S | 56.72 | 100 | 5,672 | 55,517 | 55.6 K to 55.5 K (-0.18 %) |
Nov 17 2017 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Sell | S | 56.71 | 100 | 5,671 | 55,617 | 55.7 K to 55.6 K (-0.18 %) |
Nov 17 2017 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Sell | S | 56.70 | 1,200 | 68,040 | 55,717 | 56.9 K to 55.7 K (-2.11 %) |
Nov 17 2017 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Sell | S | 56.69 | 400 | 22,676 | 56,917 | 57.3 K to 56.9 K (-0.70 %) |
Nov 17 2017 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Sell | S | 56.68 | 300 | 17,004 | 57,317 | 57.6 K to 57.3 K (-0.52 %) |
Nov 17 2017 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Sell | S | 56.67 | 300 | 17,001 | 57,617 | 57.9 K to 57.6 K (-0.52 %) |
Nov 17 2017 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Sell | S | 56.67 | 100 | 5,667 | 57,917 | 58 K to 57.9 K (-0.17 %) |
Nov 17 2017 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Sell | S | 56.66 | 100 | 5,666 | 58,017 | 58.1 K to 58 K (-0.17 %) |
Nov 17 2017 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Sell | S | 56.65 | 400 | 22,660 | 58,117 | 58.5 K to 58.1 K (-0.68 %) |
Nov 17 2017 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Sell | S | 56.63 | 200 | 11,326 | 58,517 | 58.7 K to 58.5 K (-0.34 %) |
Nov 17 2017 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Sell | S | 56.62 | 240 | 13,589 | 58,717 | 59 K to 58.7 K (-0.41 %) |
Nov 17 2017 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Sell | S | 56.60 | 200 | 11,320 | 58,957 | 59.2 K to 59 K (-0.34 %) |
Nov 17 2017 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Sell | S | 56.58 | 235 | 13,296 | 59,157 | 59.4 K to 59.2 K (-0.40 %) |
Nov 17 2017 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Sell | S | 56.57 | 65 | 3,677 | 59,392 | 59.5 K to 59.4 K (-0.11 %) |
Nov 17 2017 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Buy | M | 34.41 | 5,440 | 187,163 | 59,457 | 54 K to 59.5 K (+10.07 %) |
Nov 16 2017 | HAE | HAEMONETICS CORP | Burke Willaim P | EVP, Chief Financia ... | Option Exercise | M | 34.21 | 11,231 | 384,213 | 33,695 | |
Nov 16 2017 | HAE | HAEMONETICS CORP | Burke Willaim P | EVP, Chief Financia ... | Sell | S | 54.34 | 162 | 8,803 | 14,034 | 14.2 K to 14 K (-1.14 %) |
Nov 16 2017 | HAE | HAEMONETICS CORP | Burke Willaim P | EVP, Chief Financia ... | Sell | S | 54.33 | 100 | 5,433 | 14,196 | 14.3 K to 14.2 K (-0.70 %) |
Nov 16 2017 | HAE | HAEMONETICS CORP | Burke Willaim P | EVP, Chief Financia ... | Sell | S | 54.31 | 200 | 10,862 | 14,296 | 14.5 K to 14.3 K (-1.38 %) |
Nov 16 2017 | HAE | HAEMONETICS CORP | Burke Willaim P | EVP, Chief Financia ... | Sell | S | 54.29 | 200 | 10,858 | 14,496 | 14.7 K to 14.5 K (-1.36 %) |
Nov 16 2017 | HAE | HAEMONETICS CORP | Burke Willaim P | EVP, Chief Financia ... | Sell | S | 54.28 | 100 | 5,428 | 14,696 | 14.8 K to 14.7 K (-0.68 %) |
Nov 16 2017 | HAE | HAEMONETICS CORP | Burke Willaim P | EVP, Chief Financia ... | Sell | S | 54.23 | 100 | 5,423 | 14,796 | 14.9 K to 14.8 K (-0.67 %) |
Nov 16 2017 | HAE | HAEMONETICS CORP | Burke Willaim P | EVP, Chief Financia ... | Sell | S | 54.21 | 161 | 8,728 | 14,896 | 15.1 K to 14.9 K (-1.07 %) |
Nov 16 2017 | HAE | HAEMONETICS CORP | Burke Willaim P | EVP, Chief Financia ... | Sell | S | 54.20 | 39 | 2,114 | 15,057 | 15.1 K to 15.1 K (-0.26 %) |
Nov 16 2017 | HAE | HAEMONETICS CORP | Burke Willaim P | EVP, Chief Financia ... | Sell | S | 54.19 | 100 | 5,419 | 15,096 | 15.2 K to 15.1 K (-0.66 %) |
Nov 16 2017 | HAE | HAEMONETICS CORP | Burke Willaim P | EVP, Chief Financia ... | Sell | S | 54.17 | 100 | 5,417 | 15,196 | 15.3 K to 15.2 K (-0.65 %) |
Nov 16 2017 | HAE | HAEMONETICS CORP | Burke Willaim P | EVP, Chief Financia ... | Sell | S | 54.16 | 100 | 5,416 | 15,296 | 15.4 K to 15.3 K (-0.65 %) |
Nov 16 2017 | HAE | HAEMONETICS CORP | Burke Willaim P | EVP, Chief Financia ... | Sell | S | 54.15 | 200 | 10,830 | 15,396 | 15.6 K to 15.4 K (-1.28 %) |
Nov 16 2017 | HAE | HAEMONETICS CORP | Burke Willaim P | EVP, Chief Financia ... | Sell | S | 54.29 | 200 | 10,858 | 15,596 | 15.8 K to 15.6 K (-1.27 %) |
Nov 16 2017 | HAE | HAEMONETICS CORP | Burke Willaim P | EVP, Chief Financia ... | Sell | S | 54.10 | 200 | 10,820 | 15,796 | 16 K to 15.8 K (-1.25 %) |
Nov 16 2017 | HAE | HAEMONETICS CORP | Burke Willaim P | EVP, Chief Financia ... | Sell | S | 54.04 | 100 | 5,404 | 15,996 | 16.1 K to 16 K (-0.62 %) |
Nov 16 2017 | HAE | HAEMONETICS CORP | Burke Willaim P | EVP, Chief Financia ... | Sell | S | 54.03 | 100 | 5,403 | 16,096 | 16.2 K to 16.1 K (-0.62 %) |
Nov 16 2017 | HAE | HAEMONETICS CORP | Burke Willaim P | EVP, Chief Financia ... | Sell | S | 54.01 | 1,122 | 60,599 | 16,196 | 17.3 K to 16.2 K (-6.48 %) |
Nov 16 2017 | HAE | HAEMONETICS CORP | Burke Willaim P | EVP, Chief Financia ... | Sell | S | 54.00 | 9,909 | 535,086 | 17,318 | 27.2 K to 17.3 K (-36.39 %) |
Nov 16 2017 | HAE | HAEMONETICS CORP | Burke Willaim P | EVP, Chief Financia ... | Buy | M | 34.21 | 11,231 | 384,213 | 27,227 | 16 K to 27.2 K (+70.21 %) |
Nov 15 2017 | HAE | HAEMONETICS CORP | Goldstein Dan | Chief Accounting Of ... | Option Exercise | M | 34.21 | 1,456 | 49,810 | 4,370 | |
Nov 15 2017 | HAE | HAEMONETICS CORP | Goldstein Dan | Chief Accounting Of ... | Option Exercise | M | 34.42 | 2,607 | 89,733 | 7,821 | |
Nov 15 2017 | HAE | HAEMONETICS CORP | Goldstein Dan | Chief Accounting Of ... | Option Exercise | A | 41.64 | 4,426 | 184,299 | 4,426 | |
Nov 15 2017 | HAE | HAEMONETICS CORP | Goldstein Dan | Chief Accounting Of ... | Option Exercise | A | 34.21 | 5,826 | 199,307 | 5,826 | |
Nov 15 2017 | HAE | HAEMONETICS CORP | Goldstein Dan | Chief Accounting Of ... | Sell | S | 54.89 | 68 | 3,732 | 4,199 | 4.3 K to 4.2 K (-1.59 %) |
Nov 15 2017 | HAE | HAEMONETICS CORP | Goldstein Dan | Chief Accounting Of ... | Sell | S | 54.84 | 560 | 30,711 | 4,267 | 4.8 K to 4.3 K (-11.60 %) |
Nov 15 2017 | HAE | HAEMONETICS CORP | Goldstein Dan | Chief Accounting Of ... | Sell | S | 54.96 | 956 | 52,539 | 4,827 | 5.8 K to 4.8 K (-16.53 %) |
Nov 15 2017 | HAE | HAEMONETICS CORP | Goldstein Dan | Chief Accounting Of ... | Sell | S | 54.94 | 200 | 10,988 | 5,783 | 6 K to 5.8 K (-3.34 %) |
Nov 15 2017 | HAE | HAEMONETICS CORP | Goldstein Dan | Chief Accounting Of ... | Sell | S | 54.92 | 300 | 16,476 | 5,983 | 6.3 K to 6 K (-4.77 %) |
Nov 15 2017 | HAE | HAEMONETICS CORP | Goldstein Dan | Chief Accounting Of ... | Sell | S | 54.95 | 2,607 | 143,242 | 6,283 | 8.9 K to 6.3 K (-29.33 %) |
Nov 15 2017 | HAE | HAEMONETICS CORP | Goldstein Dan | Chief Accounting Of ... | Buy | M | 34.21 | 1,456 | 49,810 | 8,890 | 7.4 K to 8.9 K (+19.59 %) |
Nov 15 2017 | HAE | HAEMONETICS CORP | Goldstein Dan | Chief Accounting Of ... | Buy | M | 34.42 | 2,607 | 89,733 | 7,434 | 4.8 K to 7.4 K (+54.01 %) |
Nov 15 2017 | HAE | HAEMONETICS CORP | Goldstein Dan | Chief Accounting Of ... | Grant | A | 0.00 | 1,080 | 0 | 4,827 | 3.7 K to 4.8 K (+28.82 %) |
Nov 15 2017 | HAE | HAEMONETICS CORP | Goldstein Dan | Chief Accounting Of ... | Grant | A | 0.00 | 1,350 | 0 | 3,747 | 2.4 K to 3.7 K (+56.32 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Option Exercise | M | 35.50 | 10,353 | 367,557 | 0 | |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Option Exercise | M | 45.45 | 6,573 | 298,743 | 0 | |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.47 | 100 | 5,447 | 20,740 | 20.8 K to 20.7 K (-0.48 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.46 | 200 | 10,892 | 20,840 | 21 K to 20.8 K (-0.95 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.45 | 100 | 5,445 | 21,040 | 21.1 K to 21 K (-0.47 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.40 | 100 | 5,440 | 21,140 | 21.2 K to 21.1 K (-0.47 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.39 | 100 | 5,439 | 21,240 | 21.3 K to 21.2 K (-0.47 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.37 | 200 | 10,874 | 21,340 | 21.5 K to 21.3 K (-0.93 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.26 | 100 | 5,426 | 21,540 | 21.6 K to 21.5 K (-0.46 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.25 | 2,953 | 160,200 | 21,640 | 24.6 K to 21.6 K (-12.01 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.24 | 400 | 21,696 | 24,593 | 25 K to 24.6 K (-1.60 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.23 | 500 | 27,115 | 24,993 | 25.5 K to 25 K (-1.96 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.22 | 2,500 | 135,550 | 25,493 | 28 K to 25.5 K (-8.93 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.21 | 200 | 10,842 | 27,993 | 28.2 K to 28 K (-0.71 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.20 | 100 | 5,420 | 28,193 | 28.3 K to 28.2 K (-0.35 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.19 | 600 | 32,514 | 28,293 | 28.9 K to 28.3 K (-2.08 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.18 | 1,061 | 57,485 | 28,893 | 30 K to 28.9 K (-3.54 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.17 | 1,039 | 56,283 | 29,954 | 31 K to 30 K (-3.35 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.16 | 100 | 5,416 | 30,993 | 31.1 K to 31 K (-0.32 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Buy | M | 35.50 | 10,353 | 367,557 | 31,093 | 20.7 K to 31.1 K (+49.92 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.17 | 1,900 | 102,923 | 20,740 | 22.6 K to 20.7 K (-8.39 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.16 | 100 | 5,416 | 22,640 | 22.7 K to 22.6 K (-0.44 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.15 | 573 | 31,028 | 22,740 | 23.3 K to 22.7 K (-2.46 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.14 | 200 | 10,828 | 23,313 | 23.5 K to 23.3 K (-0.85 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.13 | 600 | 32,478 | 23,513 | 24.1 K to 23.5 K (-2.49 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.12 | 600 | 32,472 | 24,113 | 24.7 K to 24.1 K (-2.43 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.11 | 1,200 | 64,932 | 24,713 | 25.9 K to 24.7 K (-4.63 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.10 | 510 | 27,591 | 25,913 | 26.4 K to 25.9 K (-1.93 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.09 | 400 | 21,636 | 26,423 | 26.8 K to 26.4 K (-1.49 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.07 | 200 | 10,814 | 26,823 | 27 K to 26.8 K (-0.74 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.06 | 290 | 15,677 | 27,023 | 27.3 K to 27 K (-1.06 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Buy | M | 45.45 | 6,573 | 298,743 | 27,313 | 20.7 K to 27.3 K (+31.69 %) |